UNCOVERED: Antares pharma - The Untold Story

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027.  Antares' suite of FDA-approved and partner products utilizing…

Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of endogenous testosterone or hypogonadism. The first time the Company got a testosterone product approved by…

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.73 million in sales, a 1.12% increase since Q3.